about
Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysisTargeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinomaDevelopment of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung CancerTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsA Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona.The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphomaPrognostic significance of PD-L1 in solid tumor: An updated meta-analysis.PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressivenessPrognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study.Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningiomaPD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosisDifferential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.PD-L1 expression and prognostic impact in glioblastoma.PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with ChemotherapyImproving our understanding of papillary renal cell carcinoma with integrative genomic analysis.Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavityPrognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma.COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.Prognostic value of PDL1 expression in pancreatic cancerNivolumab in renal cell carcinoma: latest evidence and clinical potential.PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.New clinical advances in immunotherapy for the treatment of solid tumours.Future perspectives for personalized immunotherapy in renal cell carcinoma.PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma.Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC).Renal cancer subtypes: Should we be lumping or splitting for therapeutic decision making?Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?Renal cell carcinoma: molecular characterization and evolving treatment paradigms.
P2860
Q26775460-1A9D3812-AE2C-414F-B311-A5691DBCE9F5Q26775769-F8C7399B-17E3-4197-949F-53BEF8C5C82AQ26798047-BD5FBBB0-BEFD-49B7-B13D-39A11A74BAEBQ26996518-FBDA6CBC-8AE6-41F7-AAC0-A1B4ACD931BCQ33457518-01E3917C-FBCF-4740-B819-6CBD30B73C36Q33597192-35CEE423-4697-4E9C-815C-EAB0FA6E4C3AQ33644049-7C1064D6-23C3-4C38-89DA-2304F8E0D179Q33704636-7F17A48F-D447-4193-8820-E30E83F14F42Q33728267-A1DFD182-1EAA-4527-BAE2-4574FA6477DEQ35170232-0815CC8B-B267-4185-A3C7-EDAEB1293B51Q35741539-FBD7367C-3956-42A2-8264-5063F8F4B430Q35809165-0EAC8F93-32EA-495E-91AC-823A4D2CF7F6Q36132720-73B18227-A397-4A6C-B1C6-52E5E03C60A0Q36358014-11AA8BD0-5BE0-454E-8834-F61E226BDCAFQ36359469-8991B5EC-5E08-4765-9632-A3763492F08BQ36493843-4A5DF2C4-2C6A-4D68-AF10-A29A55C20649Q36707123-085D9360-9DA7-49F4-AB8D-37AC7C7B6B6CQ36829230-C250CC7F-A197-4F0E-8997-2F7F517E0F8FQ36939402-BC692D12-2149-4B4A-B380-1BC8151A765FQ37022094-CD473A71-E7B3-44FC-8966-04FA25FADBCFQ37199510-5654C78A-AE74-4839-B345-DC88EB1020BEQ37477267-58B50F95-CB4D-426D-99F3-E4EB5F3777D5Q37565108-E8CE1C30-DCDC-4E02-BDC0-D82C6B962B6BQ37609768-AB5A2FEB-931E-4962-B4FB-8973FB710DECQ37663388-23166D2B-2B59-495C-B918-FB217A0351FEQ37687595-B25027CE-BAC5-476D-8B9D-B90F10B95641Q37698611-C8D04476-8C6F-4489-A0F0-B679870D4597Q37705021-F136BF09-F902-4234-9880-42903035D12DQ37709473-56F91A94-22FC-4E8F-A9D5-58606498760AQ38397279-7F2199B3-4645-41BA-B5CA-0E2291372072Q38673583-659B27D0-10C4-4F4A-9A5D-4E2E2DA81BA6Q38788703-53905256-CE3B-43D6-BE62-933D27B87B7FQ38870624-42323388-39FB-4C81-8857-5C080BDA703DQ38870929-D53C1D4C-6920-4FD1-8372-423B4FF3CD0FQ38874291-39E0FC66-8337-441F-935A-4916322F613EQ38906250-0A1268DB-706C-4B07-97C3-3F513F3F8DE1Q38931269-7318B748-2E8D-49DE-8EC9-08D34B008682Q39012781-CE885B02-9B3F-4D19-A268-29A4F64B193AQ39120161-9D3076B2-6F7F-4A85-9619-4671696C1E27Q39157961-7D5F2401-ED95-42C5-AD47-E7A8F1888509
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
PD-L1 expression in nonclear-cell renal cell carcinoma.
@ast
PD-L1 expression in nonclear-cell renal cell carcinoma.
@en
PD-L1 expression in nonclear-cell renal cell carcinoma.
@nl
type
label
PD-L1 expression in nonclear-cell renal cell carcinoma.
@ast
PD-L1 expression in nonclear-cell renal cell carcinoma.
@en
PD-L1 expression in nonclear-cell renal cell carcinoma.
@nl
prefLabel
PD-L1 expression in nonclear-cell renal cell carcinoma.
@ast
PD-L1 expression in nonclear-cell renal cell carcinoma.
@en
PD-L1 expression in nonclear-cell renal cell carcinoma.
@nl
P2093
P2860
P356
P1433
P1476
PD-L1 expression in nonclear-cell renal cell carcinoma.
@en
P2093
D F McDermott
G J Freeman
J Bellmunt
M B Atkins
P2860
P304
P356
10.1093/ANNONC/MDU445
P577
2014-09-05T00:00:00Z